Scientific Results Presented at ECCMID Demonstrate Well-Differentiated Profile of Basilea’s Two Phase III Anti-infective Compounds
New data presented at ECCMID highlight the microbiological and pharmacokinetic profiles of Basilea’s (SWX:BSLN) two late-stage drug candidates ceftobiprole and isavuconazole. Studies reported both for ceftobiprole, the first anti-MRSA broad-spectrum cephalosporin in late-stage development, and for isavuconazole, a novel azole for the treatment of invasive fungal infections, yielded further data on their respective breadths of spectrum, and pharmacokinetic properties.
Ceftobiprole is developed in collaboration with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Eleven posters plus one oral presentation on ceftobiprole and seven posters on isavuconazole were presented at the 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), and highlighted the potentially attractive profiles of Basilea’s two late-stage development compounds.
With positive data reported for two pivotal trials in complicated skin and skin structure infections (cSSSI) ceftobiprole is approaching regulatory filing. Further evidence of the microbiological and pharmacokinetic profiles of this investigational compound was presented at ECCMID. Ceftobiprole has a broad in vitro spectrum, in particular activity against MRSA (Methicillin Resistant Staphylococcus aureus). In vitro susceptibility testing showed potent activity against all staphylococci collected in the first phase III cSSSI study, including MRSA and other multi-drug resistant pathogens (P2027). Testing these strains for the PVL gene, a marker for staphylococcal virulence, showed that the potential clinical efficacy of ceftobiprole is not impaired by the presence of this marker (P1321, O120). The antibacterial activity of ceftobiprole against Gram-positive organisms, including MRSA, is once more demonstrated in various in vitro studies (P710, P781, P784). Furthermore, ceftobiprole had the most potent activity of all beta-lactams tested against pneumococci that were not susceptible to ceftriaxone, selected from a recent US collection of clinical isolates (P2025), supporting the potential use of ceftobiprole in the treatment of pneumonia.
Further microbiological data illustrate that the in vitro activity of ceftobiprole against some of the most common Gram-negative pathogens such as the Enterobacteriaceae and Pseudomonas aeruginosa is comparable to that of extended-spectrum cephalosporins (P780, P2024, P2026). In one study, ceftobiprole showed greater in vitro potency than piperacillin/tazobactam against Pseudomonas aeruginosa (P2026).
The pharmacological characteristics of dosing ceftobiprole 500 mg three times daily with a 2-hour infusion were presented for the first time (P779). Ceftobiprole did not cause QT prolongation in a thorough QT assessment of therapeutic (500mg) and supratherapeutic (1000mg) doses (P783).
Basilea’s antifungal isavuconazole for the potential treatment of invasive fungal infections is in phase III testing in a global trial program in patients with invasive candidiasis including candidemia and patients with proven or probable aspergillosis.
New microbiological surveillance data relevant for the treatment of candidemia demonstrated isavuconazole’s superior coverage of different candida species and most fluconazole-resistant isolates compared to other azole drugs (P1978). Potent activity against candida is further supported by data from a thorough analysis in animal models (P1950). Additionally, Cryptococcus neoformans, a yeast species not typically covered by the candin class, is highly susceptible to isavuconazole (P1977).
In animal models of aspergillus infection, isavuconazole showed at relevant plasma concentrations potent efficacy against several strains of Aspergillus fumigatus including an itraconazole-resistant strain (P1951). Aspergillus fumigatus is the most frequent pathogen among the difficult-to-treat invasive mould infections.
Poster P987 showed that isavuconazole is completely bioavailable, supporting early switch to the oral dosage form in the clinic. Some azoles can cause cardiac disturbances. Isavuconazole showed no QT prolongation in the study presented (P1675).
List of Ceftobiprole Presentations
Baseline activity of ceftobiprole against methicillin-susceptible and -resistant staphylococcal clinical isolates from Europe collected in 2005-2006. T. Davies, D. Sahm, R. Flamm, K. Bush (Raritan, Herndon, US)
Pharmacokinetics of ceftobiprole following single and multiple intravenous infusions administered to healthy subjects. B. Murthy, D. Skee, D. Wexler, D. Balis, I. Chang, D. Desai-Kreiger, G. Noel (Raritan, US)
Activity of ceftobiprole tested against contemporary European Enterobacteriaceae and Pseudomonas aeruginosa (2005-2006). T. Fritsche, H. Sader, P. Strabala, R. Jones (North Liberty, US)
Activity of ceftobiprole tested against staphylococcal and streptococcal isolates recovered from patients in European medical centres (2005-2006). T. Fritsche, H. Sader, P. Strabala, R. Jones (North Liberty, US)
QT/QTc assessment of ceftobiprole in a single-dose study. D. Balis, R. Strauss, B. Murthy, H. Tiian, G. Noel (Raritan, US)
In vitro activity of ceftobirpole, dalbavancin and tigecycline against methicillin-resistant Stahpylococcus aureus strains from hospital patients in Belgium. O. Denis, C. Nonhoff, A. Deplano, M. Hallin, R. De Ryck, S. Rottiers, S. Crevecoeur, M.J. Struelens (Brussels, BE)
Regional variation in Panton-Valentine leukocidin positivity among S. aureus isolates in complicated skin and skin structure infections. R. Strauss, K. Amsler, M. Jacobs, K. Bush, G. Noel (Raritan, US)
Profile of ceftobiprole activity against S. aureus, S. pneumoniae, Enterobacteriaceae, and P. aeruginosa: results of the 2005-2006 Surveillance Program. M.K. Aranza, D.C. Draghi, M.E. Jones, C. Thornsberry, D.F. Sahm (Herndon, US; Breda, NL)
Activity of ceftobiprole against US clinical S. pneumoniae isolates that are ceftriaxone non-susceptible. T. Davies, K. Bush, P. Appelbaum (Raritan, Hershey, US)
Activity of ceftobiprole against Pseudomonas aeruginosa clinical isolates from Europe collected in 2005-2006. T. Davies, D. Sahm, R. Flamm, K. Bush (Raritan, Herndon, US)
Ceftobiprole activity and resistance patterns in staphylococcal isolates from a recent complicated skin and skin structure infection study. K. Amsler, M. Jacobs, S. Bajaksouzian, A. Windau, M. Heep, K. Bush (Raritan, Cleveland, US; Basle, CH)
Epidemiology of (CA-) MRSA (Room 13b) Characteristics of complicated skin and skin structure infections due to staphylococci and the presence of Panton-Valentine leukocidin.
R. Strauss, K. Amsler, M. Jacobs, K. Bush, G. Noel (Raritan, US)
List of Isavuconazole Presentations
Steady-state bioavailability of oral isavuconazole in healthy volunteers. A. Schmitt-Hoffmann, B. Roos, M. Heep (Basle, CH)
QTc measurements during a placebo- and actively controlled multiple dose study of two different dosing regimens of isavuconazole. M. Heep, B. Roos, M. Sochor, A. Schmitt-Hoffmann, S. Van Merle, D. Kappers, P. Voiriot (Basle, CH; Zuidlaren, NL; Nancy, FR)
Evaluation of isavuconazole (BAL8557/BAL4815) Etest compared to broth microdilution antifungal susceptibility testing against quality control strains and fluconazole susceptible clinical Candida isolates. M. Heep, P. Grover, N.P. Brown, D. Sahm, M.E. Jones (Basle, CH; Herndon, US)
Dose response in neutropenic mice with disseminated infection of multiple strains of Aspergillus fumigatus with widely varying MIC and MFC values treated with isavuconazole.P.A. Warn, A. Parmar, A. Sharp, D.W. Denning (Manchester, UK)
In vivo efficacy of the triazole BAL8557 against disseminated Candida albicans in mice assessed by survival and tissue burden in temporarily and persistently neutropenic mice treated with 1-7 doses of drug over a dose range of 20-80% of Emax. P.A. Warn, A. Parmar, A. Sharp, M. Heep, J. Spickermann, D.W. Denning (Manchester, UK; Basle, CH)
In vitro activity of isavuconazole (BAL4815/8557) compared with six other antifungal agents against 180 Cryptococcus neoformans meningitis isolates from the Netherlands. I. Curfs-Breuker, M. Illnait-Zaragozi, J. Mouton, B. Janssen, F. Hagen, L. Spanjaard, T. Boekhout, J. Meis (Nijmegen, NL; Havana, CU; Utrecht, Amsterdam, NL)
In vitro activity of isavuconazole (BAL4815) compared with seven other antifungal agents against 309 prospectively collected clinical Candida isolates from the Netherlands. I. Curfs-Breuker, J. Mouton, Y. Debets-Ossenkopp, H. Endtz, P. Verweij, J. Meis (Nijmegen, Amsterdam, Rotterdam, NL)
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.